Home

The Duke Human Vaccine Institute (DHVI) has established a place of national and international leadership in the fight against major infectious diseases. DHVI plays an integral leadership role in the Global HIV/AIDS Vaccine Enterprise and is a pioneer in emerging infections and biodefense research. By focusing on the scientific “bottlenecks” for the development of HIV, TB, and other vaccines, DHVI investigators continue to make significant contributions to overcome global health challenges on behalf of society.

Press Releases

Electron Microscopy Image of the Human Immunodeficiency Virus
See older Press Releases

Announcements

DHVI selected as the "Best Academic Research Team" by the World Vaccine Congress
World Vaccine Congress
April 19, 2013

Bart Haynes discusses the future of HIV-1 vaccine development
Official Press Conference at the XIX International AIDS Conference
July 25, 2012

Bart Haynes presents on the future of HIV-1 vaccine development
XIX International AIDS Conference
July 25, 2012

See more Announcements

Publications

Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int. 2013 Apr 20. doi: 10.1111/liv.12202. [Epub ahead of print] Abstract

Barrigan LM, Tuladhar S, Brunton JC, Woolard MD, Chen CJ, Saini D, Frothingham R, Sempowski GD, Kawula TH, Frelinger JA. Infection with Francisella tularensis LVS clpB Leads to an Altered yet Protective Immune Response. Infect Immun. 2013 Jun;81(6):2028-42. doi: 10.1128/IAI.00207-13. Abstract

All Publications